Manufacturers may need to modify vaccines to protect against new coronavirus variants - U.S. FDA

(Reuters) - If vaccine developers struggle to induce immune reaction in their current form, the U.S. health regulator said on Monday, vaccine developers will need to change their vaccines to provide safety against possible emerging coronaviral strains in the US.

"At this time, available information suggests that the FDA-authorized vaccines remain effective in protecting the American public against currently circulating strains of SARS-CoV-2," the United States.

The Administration of Food and Drug said in a statement.

The Department commented in the recently revised recommendation to businesses making COVID-19 vaccinations, tests and therapeutics.


The introduction of new, more infectious strains has inspired the U.S. government to step up attempts to detect variations of coronavirus and preserve vaccines and therapies effective against all new variants.

The FDA recommended that vaccine manufacturers assess any changed vaccines in both previously inaccessible and vaccinated persons as part of its revised guide.

The manufacturers should compare the immune reaction both to the current version and the original virus of a revamped vaccine.

The FDA has recommended that the welfare of test subjects be checked for at least seven days in order to justify an immediate use license for updated vaccines.

(Manojna Maddipatla's report in Bengaluru; Jonathan Oatis editing)